This biopharmaceutical company develops and markets hypoxia-inducible factor (HIF) drugs for the treatment of kidney disease, notably Vadadustat.
This biopharmaceutical company develops and markets hypoxia-inducible factor (HIF) drugs for the treatment of kidney disease, notably Vadadustat.